BDAZ – Looks like they designed this assay in 2013. I took a brief scan of the US Patent Office web site and did not find anything that looked like a Patent filing for this test by Zenith. It might not show up until it is accepted or rejected. The test itself could be a future revenue generator for the company, although having the drug approved would be much more profitable for us.

We designed, developed, and validated a whole blood PD marker assay to detect the activity of ZEN-3694, an orally available inhibitor of the bromodomain and extra-terminal (BET) domain family of proteins currently in phase I clinical trials in mCRPC (NCT02705469 and NCT02711956). 

https://google2.fda.gov/search?q=Zenith+Epigenetics&client=FDAgov&site=FDAgov&lr=&proxystylesheet=FDAgov&requiredfields=-archive%3AYes&output=xml_no_dtd&getfields=*

For those of us that have been around since 2006/2007 it looks like Coco the monkey is back to help us (old joke) on the Zenith side of the business.

In vivo validation was also done in whole blood obtained from xenograft mice, and cynomolgus monkeys that were dosed orally with ZEN-3694, as well as ex-vivo treated human blood derived from normal donors or patients diagnosed with either AML or diffuse large B cell lymphoma.

tada